A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
Latest Information Update: 25 Mar 2022
At a glance
- Drugs Quisovalimab (Primary) ; Corticosteroids; Remdesivir
- Indications Acute lung injury; Adult respiratory distress syndrome; COVID 2019 infections; COVID-19 pneumonia; Cytokine release syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Aevi Genomic Medicine
Most Recent Events
- 01 Feb 2022 Results published in the Journal of Clinical Investigation
- 13 May 2021 According to a Cerecor media release, CERC-002 received Fast Track Designation from the U.S. Food and Drug Administration, following positive Phase 2 clinical trial for the treatment of patients hospitalized with COVID-19 ARDS
- 02 Mar 2021 Primary endpoint (Proportion of patient alive and free of respiratory failure) has been met, according to a Cerecor media release